125 related articles for article (PubMed ID: 16627301)
21. Evaluation on drug dependence of buprenorphine.
Liu ZM; Lü XX; Lian Z; Mu Y; Guo P; An X
Acta Pharmacol Sin; 2003 May; 24(5):448-52. PubMed ID: 12740181
[TBL] [Abstract][Full Text] [Related]
22. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal.
Doran CM; Shanahan M; Bell J; Gibson A
Drug Alcohol Rev; 2004 Jun; 23(2):171-5. PubMed ID: 15370023
[TBL] [Abstract][Full Text] [Related]
23. Counseling plus buprenorphine-naloxone for opioid dependence.
Gorelick DA
N Engl J Med; 2006 Oct; 355(16):1736; author reply 1736-7. PubMed ID: 17050900
[No Abstract] [Full Text] [Related]
24. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
25. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
26. Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance.
Singhal A; Tripathi BM; Pal HR; Jena R; Jain R
Addict Behav; 2007 Feb; 32(2):320-31. PubMed ID: 16814937
[TBL] [Abstract][Full Text] [Related]
27. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
28. [Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians].
De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A27-32. PubMed ID: 10855374
[TBL] [Abstract][Full Text] [Related]
29. Economic and social effects of high-dose buprenorphine substitution therapy. Six-month results.
Lavignasse P; Lowenstein W; Batel P; Constant MV; Jourdain JJ; Kopp P; Reynaud-Maurupt C; Riff B; Videau B; Mucchielli A
Ann Med Interne (Paris); 2002 May; 153(3 Suppl):1S20-6. PubMed ID: 12218879
[TBL] [Abstract][Full Text] [Related]
30. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
31. [Buprenorphine as opioid substitution to pregnant addicts].
Rasmussen ET; Nielsen LB
Ugeskr Laeger; 2003 Sep; 165(38):3607-8. PubMed ID: 14556390
[No Abstract] [Full Text] [Related]
32. [Maintaining opioid abstinence long after inpatient treatment with opioid substitution in an addictology hospital unit].
Bouab O; Lahmek P; Meunier N; Aubin HJ; Michel L
Rev Med Brux; 2013; 34(3):132-40. PubMed ID: 23951853
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
34. The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols.
George S; George C; Chauhan M
Forensic Sci Int; 2004 Jul; 143(2-3):121-5. PubMed ID: 15240031
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
[TBL] [Abstract][Full Text] [Related]
36. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.
White J; Bell J; Saunders JB; Williamson P; Makowska M; Farquharson A; Beebe KL
Drug Alcohol Depend; 2009 Jul; 103(1-2):37-43. PubMed ID: 19403243
[TBL] [Abstract][Full Text] [Related]
37. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
Winstock AR; Lea T; Ritter A
Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
[TBL] [Abstract][Full Text] [Related]
38. Managing opioid addiction with buprenorphine.
Donaher PA; Welsh C
Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
[TBL] [Abstract][Full Text] [Related]
39. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
[TBL] [Abstract][Full Text] [Related]
40. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.
Lintzeris N
Drug Alcohol Rev; 2002 Mar; 21(1):39-45. PubMed ID: 12189003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
